Polydeoxyribonucleotide (PDRN) Testing: Analytical Methods, Quality Parameters, and Regulatory Frame

Polydeoxyribonucleotide (PDRN) testing is a critical quality control process for verifying the identity, purity, molecular weight distribution, and safety of DNA-derived polymers used in regenerative medicine, aesthetic injectables, and advanced cosmetic formulations. This technical article provides a comprehensive overview of PDRN sample types, testing items, analytical methods, applicable standards, and practical application scenarios to support manufacturers, regulatory professionals, and quality assurance teams.

Technical Overview

Polydeoxyribonucleotide (PDRN) is a linear polymer composed of deoxyribonucleotide monomers, most commonly derived from the purified DNA of salmonid species such as chum salmon (Oncorhynchus keta) or trout milt. Through controlled extraction, thermal or enzymatic depolymerization, and multi-step purification, pharmaceutical-grade PDRN with a defined molecular weight distribution—typically ranging from 50 kDa to 1,500 kDa—is obtained. Its documented regenerative activity is attributed to the stimulation of adenosine A2A receptors and the supply of nucleotides through the salvage pathway, which promotes fibroblast proliferation, collagen synthesis, angiogenesis, and accelerated tissue repair.

Because PDRN is a biologically derived active substance, comprehensive analytical characterization is essential to demonstrate identity, quantify active content, control molecular weight distribution, and exclude process- and origin-related impurities such as residual proteins, nucleases, endotoxins, residual solvents, and elemental contaminants. Structured PDRN testing programs support regulatory submissions for injectable products, cosmetic safety dossiers, and medical device biocompatibility files, and are typically executed by accredited third-party laboratories operating under ISO/IEC 17025 quality management systems.

Testing Samples

Bulk Drug Substance (PDRN Powder and Sodium Salt)

Lyophilized PDRN and its more stable sodium salt form represent the primary materials for characterization. Because PDRN powder is highly hygroscopic, sampling must be performed under controlled humidity conditions. Key evaluations include identity confirmation, DNA assay, molecular weight distribution, residual protein, water content, and elemental impurities.

Sterile Injectable PDRN Solutions

Finished injectable products supplied in pre-filled syringes, ampoules, or vials require finished-product testing, including sterility, bacterial endotoxins, pH, osmolality, visible and subvisible particulate matter, and content uniformity across the shelf life.

Cosmetic and Dermocosmetic Formulations

PDRN-containing serums, creams, and ampoule concentrates present analytical challenges due to complex matrices and potential interference from preservatives, peptides, and humectants. Validated extraction and recovery procedures are required before spectrophotometric or chromatographic quantification can be considered reliable.

Combination Products and Biomaterials

PDRN-loaded hydrogels, dermal scaffolds, sutures, and wound dressings are tested for released active content, extractables and leachables, and biocompatibility in accordance with the ISO 10993 series for biological evaluation of medical devices.

Starting Materials and Process Intermediates

Crude salmon milt DNA and depolymerization intermediates are verified for species authenticity, degree of depolymerization, and absence of degradation contaminants to ensure traceability from raw material to finished product.

Testing Items

A complete PDRN testing protocol typically encompasses the following quality attributes:

• Identification: UV absorption spectrum with maximum at 260 nm, A260/A280 ratio of 1.7–2.0, FTIR fingerprint comparison against a reference standard, and confirmation of the deoxyribose backbone via the diphenylamine colorimetric reaction.
• Assay (DNA content): Quantification of polydeoxyribonucleotide content, with pharmaceutical-grade specifications commonly set at not less than 95% on a dried basis.
• Molecular weight distribution: Determination of average molecular weight and the distribution range, a critical parameter directly linked to biological activity and release kinetics.
• Residual protein content: Typically limited to not more than 1%, measured by colorimetric protein assays.
• Nucleic acid impurities: Detection of single-stranded DNA fragments, residual RNA, and free nucleotides.
• Nuclease activity: Verification of DNase and RNase absence to guarantee product stability.
• Bacterial endotoxins: Limulus amebocyte lysate (LAL) testing against product-specific limits calculated according to internationally recognized pharmacopoeial formulas.
• Sterility and bioburden: Sterility testing for injectables and microbial limit testing for topical products.
• Elemental impurities: Quantification of heavy metals and elemental contaminants by ICP-MS against class-based permissible exposure limits.
• Residual solvents: Determination of extraction-related solvents such as ethanol, phenol, and chlorinated hydrocarbons by headspace gas chromatography.
• Physicochemical parameters: pH, osmolality, water content (Karl Fischer titration), and particulate matter.
• Biocompatibility: Cytotoxicity, sensitization, irritation, intracutaneous reactivity, and genotoxicity evaluations per the ISO 10993 series where clinically indicated.
• Stability studies: Long-term, accelerated, and stress-condition testing to establish shelf life and storage conditions.

Testing Methods

Spectrophotometric Methods

UV-Vis spectrophotometry is the primary tool for both identification and assay. Quantification is performed at 260 nm using the established extinction coefficient for DNA, while the A260/A280 and A260/A230 ratios provide rapid screening for protein and organic contamination. FTIR spectroscopy delivers a structural fingerprint, and nuclear magnetic resonance (1H-NMR and 31P-NMR) confirms the phosphodiester backbone integrity in high-specification programs.

Chromatographic Methods

Size-exclusion chromatography (SEC), particularly when coupled with multi-angle light scattering detection (SEC-MALS), provides absolute molecular weight determination without reliance on column calibration standards. Following enzymatic digestion to constituent nucleotides, ion-pair reversed-phase HPLC or anion-exchange chromatography verifies nucleotide composition and purity, while GC headspace analysis addresses residual solvents.

Electrophoretic Methods

Agarose gel electrophoresis with an appropriate DNA ladder offers a straightforward visualization of fragment size distribution, detecting both over-depolymerized low-molecular-weight fractions and insufficiently depolymerized high-molecular-weight species.

Colorimetric and Enzymatic Assays

The diphenylamine (Dische) reaction selectively detects deoxyribose and distinguishes PDRN from RNA-based polynucleotides. Bicinchoninic acid (BCA) or Bradford assays quantify residual proteins, and enzymatic fluorescence assays confirm the absence of nuclease activity.

Microbiological and Endotoxin Methods

Endotoxin testing is conducted using gel-clot, kinetic turbidimetric, or chromogenic LAL techniques. Sterility testing follows membrane filtration or direct inoculation methods, while cosmetic products are evaluated against ISO 17516 microbiological limits, with enumeration and specified organism detection performed per ISO 21149 and related ISO methods.

Elemental and Molecular Biology Methods

Applications

PDRN testing services support a diverse range of product categories and development stages:

• Regenerative pharmaceuticals: Quality control of PDRN injections indicated for wound healing, diabetic foot ulcers, periodontal tissue regeneration, and intra-articular cartilage repair.
• Aesthetic dermatology: Verification of skin booster injectables, mesotherapy solutions, scalp regeneration products, and post-procedure recovery formulations.
• Functional cosmetics: Safety and content substantiation for anti-aging serums and dermocosmetic concentrates marketed under cosmetic regulations, including GB and ISO cosmetic safety frameworks.
• Medical devices and combination products: Biocompatibility and extractables/leachables evaluation of PDRN-coated implants, hydrogels, and scaffolds per the ISO 10993 series.
• Veterinary medicine: Quality assurance of PDRN preparations for companion animal wound management and joint therapy.
• Research and development: Lot release testing of research-grade PDRN used as a cell culture supplement in regenerative biology studies.

FAQ

What is the difference between PDRN and polynucleotide (PN) products?

PDRN refers specifically to a DNA-derived polymer of deoxyribonucleotides, typically with a long linear chain structure, whereas PN products may combine DNA and RNA-derived fragments with different molecular weight profiles. The diphenylamine reaction and chromatographic nucleotide profiling are used to definitively distinguish the two materials.

Why is molecular weight distribution so important in PDRN testing?

Molecular weight directly influences biological activity, viscosity, diffusion behavior in tissue, and release kinetics from delivery systems. An overly broad or shifted distribution may indicate inconsistent depolymerization and can compromise clinical performance, making SEC-MALS and gel electrophoresis verification essential batch-release criteria.

What endotoxin limits apply to injectable PDRN products?

Endotoxin limits are calculated on a product-specific basis according to the internationally harmonized formula of the maximum allowable human dose per kilogram per hour, and are verified by validated LAL methods. Accredited third-party laboratories confirm method suitability in the presence of the PDRN matrix to rule out interference.

How is residual protein controlled in PDRN manufacturing?

Because PDRN originates from biological tissue, residual protein is a critical impurity. Sequential purification steps reduce protein to below 1%, and each batch is confirmed by BCA or Bradford assay, with the A260/A280 ratio serving as an additional in-process indicator.

What sample quantities are typically required for a full test panel?

A complete characterization program covering identity, assay, molecular weight, purity, endotoxin, sterility, and elemental impurities generally requires several hundred milligrams of bulk powder or a minimum of three finished-product units. Exact requirements depend on the dosage form and the validated analytical methods applied.